Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition the regulation of target ADME gene expression.
10.1016/j.apsb.2018.12.002
- Author:
Xin LI
1
;
Ye TIAN
2
;
Mei-Juan TU
3
;
Pui Yan HO
3
;
Neelu BATRA
3
;
Ai-Ming YU
3
Author Information
1. Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.
2. Lab for Bone Metabolism, Key Lab for Space Biosciences and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi׳an 710072, China.
3. Department of Biochemistry & Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA.
- Publication Type:Journal Article
- Keywords:
3′-UTR, 3′-untranslated region;
, VDR, vitamin D receptor;
ABCG2;
ABCG2, ATP-binding cassette sub-family G member 2;
, ADME, absorption, distribution, metabolism, and excretion;
BERA, bioengineered RNA agent;
, CYP, cytochrome P450;
Bioengineered RNA;
CYP3A4;
Drug disposition;
E. coli, Escherichia coli;
, FPLC, fast protein liquid chromatography;
LC--MS/MS, liquid chromatographytandem mass spectroscopy;
, microRNA, miR or miRNA;
RNAi, RNA interference;
, RT-qPCR, reverse transcription quantitative real-time polymerase chain reaction;
RXRα, retinoid X receptor α;
, tRNA, transfer RNA;
miR-27b;
miR-328;
ncRNA, noncoding RNA;
, PAGE, polyacrylamide gel electrophoresis
- From:
Acta Pharmaceutica Sinica B
2019;9(3):639-647
- CountryChina
- Language:English
-
Abstract:
Drug-metabolizing enzymes, transporters, and nuclear receptors are essential for the absorption, distribution, metabolism, and excretion (ADME) of drugs and xenobiotics. MicroRNAs participate in the regulation of ADME gene expression imperfect complementary Watson-Crick base pairings with target transcripts. We have previously reported that Cytochrome P450 3A4 (CYP3A4) and ATP-binding cassette sub-family G member 2 (ABCG2) are regulated by miR-27b-3p and miR-328-3p, respectively. Here we employed our newly established RNA bioengineering technology to produce bioengineered RNA agents (BERA), namely BERA/miR-27b-3p and BERA/miR-328-3p, fermentation. When introduced into human cells, BERA/miR-27b-3p and BERA/miR-328-3p were selectively processed to target miRNAs and thus knock down and mRNA and their protein levels, respectively, as compared to cells treated with vehicle or control RNA. Consequently, BERA/miR-27b-3p led to a lower midazolam 1'-hydroxylase activity, indicating the reduction of CYP3A4 activity. Likewise, BERA/miR-328-3p treatment elevated the intracellular accumulation of anticancer drug mitoxantrone, a classic substrate of ABCG2, hence sensitized the cells to chemotherapy. The results indicate that biologic miRNA agents made by RNA biotechnology may be applied to research on miRNA functions in the regulation of drug metabolism and disposition that could provide insights into the development of more effective therapies.
